Furthermore, a systematic meta-analysis by Scirocchi F et al. that involved 1076 patients across various tumor types treated with immunotherapy indicated that elevated circulating sPD-L1 levels in cancer patients are associated with poorer survival, suggesting its potential as a prognostic biomarker for patient selection before immunotherapy [9]. Here, SPDL1 is linked to cancer.